<DOC>
	<DOC>NCT00707187</DOC>
	<brief_summary>Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel features of scleroderma. This includes Raynaud phenomenon as well as the vaginal dryness and discomfort associated with scleroderma</brief_summary>
	<brief_title>Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Female with diagnosis of scleroderma Stable sexual relationship with male partner or be sexually active Raynaud phenomenon at least 6 times per week Willing to attempt sexual activity 1/month during study period Severe internal organ problems related to scleroderma Other gynecologic problems Serious depression Receiving other experimental and Raynaud treatments</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>raynaud phenomenon</keyword>
</DOC>